Improving Sexual Health In Men With Prostate Cancer: Randomised Controlled Trial Of Exercise And Psychosexual Therapies
Funder
National Health and Medical Research Council
Funding Amount
$583,416.00
Summary
Sexual dysfunction is one of the most common and distressing side effects of prostate cancer. Despite being a critical survivorship care issue, there is a clear gap in knowledge surrounding the optimal treatment of sexual dysfunction in men with prostate cancer. This project examines whether exercise aids in the management of sexual dysfunction and explores if an integrated treatment model incorporating pharmacological, exercise and psychosexual therapies maximises improvement in sexual health.
Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
Which Modifiable Risk Factors Actually Cause Cancer?
Funder
National Health and Medical Research Council
Funding Amount
$384,076.00
Summary
Observational studies suggest that modifiable risk factors such as low vitamin D levels, coffee consumption, alcohol consumption and obesity may be important in cancer risk. However, observational studies can only demonstrate association between a risk factor and cancer, and association does not equal causation. We present an alternative approach to help determine which risk factors actually cause cancer.
Physiologically-based Pharmacokinetics And Pharmacodynamics Of Therapeutic Stem Cells For Liver Disease
Funder
National Health and Medical Research Council
Funding Amount
$848,710.00
Summary
This project focuses on the challenging area of effective and optimal dosing cell-based therapy for liver diseases. We will investigate the fate and therapeutic effects of natural, modified and artificial therapeutic cells in the body and in liver regions using a physiologically-based kinetic model. Our key goal is advance cell therapy by providing a better understanding and dosing guidelines.
DsbA Foldases From Multidrug Resistant Pathogens As Targets For New Antimicrobials
Funder
National Health and Medical Research Council
Funding Amount
$743,401.00
Summary
Bacteria that cause common human infections, such as cystitis and diarrhoea, are now resistant to many antibiotics. If no action is taken, by 2050 antibiotic resistant infections will kill more people each year than cancer. This project aims to address this global public health crisis by characterising promising new bacterial targets and inhibitors designed to disarm multidrug resistant pathogens. Longer term this work could provide new infection therapies that are urgently needed.
KLK4 Is A Master Regulator Of Tumour Microenvironment Remodelling In Prostate Cancer And Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$596,305.00
Summary
The current biomarker for prostate cancer, PSA, belongs to a large family of related proteins called KLK enzymes. We have evidence that one of these enzymes, KLK4, regulates many different pathways involved in tumour spreading especially to bones. This project will determine the specific components involved with a view to finding better biomarkers of tumour spread and bone metastasis and designing better treatments for these aspects of the disease.
We have identified genetic abnormalities in 5% of breast cancers that fall in a novel DNA element called BIME1. This proposal aims to determine whether these genetic abnormalities contribute to breast tumourigenesis and which genes and pathways are affected by these mutations. The outcomes of this proposal may lead to the development of novel therapies for breast cancer or could influence the choice of existing therapies for patients that harbour these genetic abnormalities.
A Prospective Study Of Language Impairment And Recovery Following Surgery For Brain Tumours
Funder
National Health and Medical Research Council
Funding Amount
$861,342.00
Summary
This multi-site project will investigate the incidence and nature of post-operative language difficulties (aphasia) in patients following surgery for left hemisphere primary brain tumours. It will provide comprehensive data concerning risk factors for post-surgical aphasia in Australian patients, in addition to important information about the brain lesions responsible for its various clinical presentations. This information will be used to generate recommendations for clinical practice.
Cultivated Corneal Endothelial Cell Implants For Restoring Vision
Funder
National Health and Medical Research Council
Funding Amount
$886,032.00
Summary
Thousands of Australians each year receive a corneal tissue transplant from the eyes of a deceased organ donor. In the majority of cases these transplants are performed to restore structure and function to the most posterior layer of the cornea – the corneal endothelium. The reliance upon donor tissue, however, presents significant logistical and safety issues. Our goal is therefore to develop improved strategies for treating diseases of the corneal endothelium using cultivated tissue implants.
Fighting Epidermal Skin Cancers By Targeting Epidermal Clones That Accumulate Mutations
Funder
National Health and Medical Research Council
Funding Amount
$1,149,373.00
Summary
Common skin cancers such as basal and squamous cell carcinomas (BCC and SCC) are by far the most frequent cancer worldwide and require over a million interventions per year in Australia. This project will identify the skin cells that are most susceptible to give rise to cancer if excessively exposed to the sun and explores ways to prevent cancer formation. This will inform on new strategies to prevent new skin cancer development.